Heartseed (219A) · RiskMitigated
Unexpected safety risks in clinical trials
First written in FY2024. 4 of 5 entries say "Mitigated", first in FY2025. Latest entry: 2026-08-31.
5entries
2years
3from disclosures
How it moved
Same theme, other companies
Health Damage from Pharmaceuticals and Product Liability RiskA theme 59 companies write about · 68 as a headwind · 1 as a tailwind
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
9 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 59 companies compared. The sentences above are computed from all 59.Full recordFilings, disclosures and news, newest first
- FY2025MitigatedAnnual report
「Neither tumor formation, refractory ventricular arrhythmia nor serious adverse events that would interfere with continuation of the trial was observed in either the low-dose group at 52 weeks or the high-dose group at 26 weeks.」
During the periods observed in the LAPiS trial, 52 weeks for the low-dose group and 26 weeks for the high-dose group, no tumor formation, refractory ventricular arrhythmia or serious adverse events that would interfere with trial continuation was observed. However, the Company has not ruled out unexpected safety concerns in future trials. - FY2024First statedAnnual report
「However, it cannot currently be completely ruled out that unexpected safety concerns not anticipated in advance may arise after the LAPiS trial moves to the high-dose stage or in future clinical trials involving cardiomyocytes.」
The Company identifies the possibility of unexpected safety concerns, including tumor formation and arrhythmia, during clinical development, including after high-dose administration.